# DNA Methylation Testing for the Screening of Uterine Cervical Lesion

> **NCT04646954** · PHASE3 · UNKNOWN · sponsor: **Lei Li** · enrollment: 12000 (estimated)

## Conditions studied

- Cervical Cancer
- Cervical Intraepithelial Neoplasia
- DNA Methylation
- High-risk Human Papillomavirus
- Cytology

## Interventions

- **DIAGNOSTIC_TEST:** Host DNA methylation testing
- **DIAGNOSTIC_TEST:** Cervical cytology and/or high-risk human papillomavirus assays

## Key facts

- **NCT ID:** NCT04646954
- **Lead sponsor:** Lei Li
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-26
- **Primary completion:** 2022-11-26
- **Final completion:** 2022-11-26
- **Target enrollment:** 12000 (ESTIMATED)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04646954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04646954, "DNA Methylation Testing for the Screening of Uterine Cervical Lesion". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04646954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*